Content - Volume , Issue
You can find all new content after October 1 on our new website, you can find it
here.
All articles
CLINICAL REPORT
Antonio Costanzo, Filomena Russo, Marco Galluzzo, Luca Stingeni, Roberta Scuderi, Leonardo Zichichi, Manuela Papini, Luisa Di Costanzo, Andrea Conti, Martina Burlando, Andrea Chiricozzi, Francesca Maria Gaiani, Cristina Mugheddu, Maria Letizia Musumeci, Paolo Gisondi, Stefano Piaserico, Paolo Dapavo, Marina Venturini, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Ketty Peris, Franca Cantoresi, Sara Trevisini, Francesco Loconsole, Annamaria Offidani, Santo Raffaele Mercuri, Viviana Lora, Francesca Prignano, Marta Bartezaghi, Giovanni Oliva, Elisabetta Aloisi, Roberto Orsenigo for the SUPREME study group
Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 respon ...
Page: 0
SHORT COMMUNICATION
Emmanuel Ribereau-Gayon, Joann Le Borgne De Lavillandre, Thibaut Deschamps, Brigitte Balme, Olivier Harou, Florent Grange
Abstract is missing (Short Communication)
Page: 0
CLINICAL REPORT
Lieneke F.M. Ariëns, Daphne S. Bakker, Lotte S. Spekhorst, Jorien van der Schaft, Judith L. Thijs, Inge Haeck, Annebeth E. Flinterman, Marijke Kamsteeg, Marie L.A. Schuttelaar, Marjolein S. De Bruin-Weller
Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay ...
Page: 0
SHORT COMMUNICATION
Karim Souaid, Bénédicte Oulès, Pierre Sohier, Lydia Deschamps, Sélim Aractingi, Nicolas Dupin
Abstract is missing (Short communication)
Page: 0
INVESTIGATIVE REPORT
Maximilian Reinhardt, Claudia Garbe, Jana Petersen, Matthias Augustin, Natalia Kirsten, Mona H.C. Biermann, Benjamin Häberle, Kristina Hagenström
Psoriatic arthritis is a frequent manifestation of psoriasis, and has a high level of impact on physical functioning, work ability and quality of life. However, there have been few studies of the epidemiology, development of and risk factors for concomitant psoriatic arthritis in patients with psoriasis. This study analysed data from a German public health insurance database of > 2 million indiv ...
Page: 0
REVIEW
Agnieszka Kaczorowska, Lidia Rudnicka, Catherine M. Stefanato, Anna Waskiel-Burnat, Olga Warszawik-Hendzel, Malgorzata Olszewska, Adriana Rakowska
Trichotillomania is formally classified as a mental health disorder, but it is commonly diagnosed by dermatologists. The aim of this systematic review is to assess the diagnostic value of trichoscopy in diagnosing trichotillomania. The analysis identified the 7 most specific trichoscopic features in trichotillomania. These features had the following prevalence and specificity: trichoptilosis (57.5 ...
Page: 0
QUIZ
Cassandre Pottier, Annabel Maruani, Fanny Dujardin, Juliette Robert
Abstract is missing (Quiz)
Page: 0
INVESTIGATIVE REPORT
Leigh A. Nattkemper, Kaining Zhi, Kaeli E. Romero, Serena M. Shah, Terresa Ju, Kayla Fourzali, Rachel Shireen Golpanian, Flor MacQuhae, Yiong Huak Chan, David B. Lebo, Gil Yosipovitch
There is a need for new topical antipruritics that are effective on many types of itch. This study examined the antipruritic efficacy of a new formulation of topical acetaminophen. In vitro skin permeability studies showed that 2.5% and 5% formulations are able to rapidly deliver an adequate amount of the drug into the skin. In a double-blind, vehicle-controlled, randomized study in 17 healthy vol ...
Page: 0
CLINICAL REPORT
Angèle Soria, Claire Thénié, Christina Bienenfeld, Delphine Staumont-Sallé
It is important to understand patients’ and dermatologists’ perceptions of various aspects of atopic dermatitis, but there is a lack of studies on quality of life and stakeholder viewpoints in this therapy area. The aim of this study was to compare patients’ and dermatologists’ viewpoints regarding the impact of atopic dermatitis that is uncontrolled by topical corticosteroids. Data were c ...
Page: 0
SHORT COMMUNICATION
Jin-Yuan Ma, Tian Chen, Dong-Lai Ma
Abstract is missing (Quiz)
Page: 0
INVESTIGATIVE REPORT
Silvia Mariel Ferrucci, Simona Tavecchio, Luisa Angileri, Teresa Surace, Emilio Berti, Massimiliano Buoli
The aim of this study was to detect demographic and clinical factors associated with affective symptoms and quality of life in patients with severe atopic dermatitis. First, one-way analyses of variance and correlations were performed to compare a large set of qualitative and quantitative clinical variables. Three final multivariable regression models were performed, with depression/anxiety subsca ...
Page: 0
REVIEW
Ahmed A. Hawash, Giuseppe Ingrasci, Keyvan Nouri, Gil Yosipovitch
Keloids are scars that extend beyond the margins of an insulting cutaneous injury. Keloids are often thought to be primarily a cosmetic issue, as they are typically quite raised and pigmented. However, these scars also present with functional symptoms of pruritus and pain that significantly impact quality of life. The symptom of pruritus is frequently overlooked by dermatologists, and treatments a ...
Page: 0
INVESTIGATIVE REPORT
Michael Brandwein, Garold Fuks, Avigail Israel, Emmilia Hodak, Fareed Sabbah, Doron Steinberg, Zvi Bentwich, Noam Shental, Shiri Meshner
The bacterial population that colonizes the human face imparts physiochemical and physiological effects on the facial skin. These skin-microbe interactions impact dermatological, cosmetic and skincare applications due to the centrality of the human face in daily interactions. However, fine-scale characterization of the human face skin microbiome is lacking. Using 16S rRNA sequencing and 3D cartogr ...
Page: 0
CLINICAL REPORT
Florence Poizeau, Sébastien Barbarot, Yannick Le Corre, Emilie Brenaut, Mahtab Samimi, Hélène Aubert, Alexis Toubel, Alain Dupuy
Numerous cases of chilblains have been observed associated with the COVID-19 pandemic. The aims of this study were to provide comprehensive follow-up data for patients reporting chilblains, and to determine the risk factors for incomplete recovery. Patients referred to 5 hospitals in France between March and May 2020 for chilblains were surveyed on December 2020. A teleconsultation was offered. Am ...
Page: 0
SHORT COMMUNICATION
Luca Stingeni, Marta Tramontana, Lorenzo Cordera, Michela Castello, Aurora Parodi
Abstract is missing (Short communication)
Page: 0
SHORT COMMUNICATION
Minna E. Kubin, Ulla Lantto, Outi Lindgren, Kaisa Tasanen
Abstract is missing (Short communication)
Page: 0
SHORT COMMUNICATION
Daniel Mazzoni, Jim Muir
Abstract is missing (Short communication)
Page: 0
INVESTIGATIVE REPORT
Jochen H.O. Hoffmann, Christian Knoop, Alexander Enk, Eva N. Hadaschik
Psoriasis is thought to be associated with a reduced life expectancy through systemic inflammation. A comparative, retrospective analysis of neutrophil-to-lympho-cyte ratio, a biomarker of systemic inflammation and cardiovascular risk, under 196 treatments with tumour necrosis factor-α and interleukin-12/23 antagonists was performed. Neutrophil-to-lympho-cyte ratio decreased significantly within ...
Page: 0
SHORT COMMUNICATION
Valérie Peeters, Sherief R. Janmohamed, Samira Baharlou, Jan Gutermuth, Ria Willemsen
Abstract is missing (Short communication)
Page: 0
CLINICAL REPORT
Sam Polesie, Lisa Sundback, Martin Gillstedt, Hannah Ceder, Johan Dahlén Gyllencreutz, Julia Fougelberg, Eva Johansson Backman, Jenna Pakka, Oscar Zaar, John Paoli
Several melanoma-specific dermoscopic features have been described, some of which have been reported as indicative of in situ or invasive melanomas. To assess the usefulness of these features to differentiate between these 2 categories, a retrospective, single-centre investigation was conducted. Dermoscopic images of melanomas were reviewed by 7 independent dermatologists. Fleiss’ kappa (κ) was ...
Page: 0
SHORT COMMUNICATION
Magdalena Żychowska, Joanna Muda-Urban, Kamila Jaworecka, Ewa Kaznowska, Adam Reich
Abstract is missing (Short communication)
Page: 0
CLINICAL REPORT
Riccardo G. Borroni, Piergiorgio Malagoli, Luigi Gargiulo, Mario Valenti, Giulia Pavia, Paola Facheris, Emanuela Morenghi, Isotta Giunipero di Corteranzo, Alessandra Narcisi, Michela Ortoncelli, Paolo Dapavo, Antonio Costanzo
Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in monotherapy up to week 40 in a “real-life” setting. At week 40, 98.7%, 85.7% and 62.3% of patients a ...
Page: 0
